HIS
ZNTL icon

Harvest Investment Services’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Harvest Investment Services’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,206
Closed -$21.5K – 390
2025
Q3 		$21.5K Sell
14,206
-11,266
-44% -$16.9K ﹤0.01% 318
2025
Q2 		$29.5K Buy
25,472
+705
+3% +$930 0.01% 318
2025
Q1 		$39.4K Sell
24,767
-23,913
-49% -$51.6K 0.01% 277
2024
Q4 		$148K Buy
+48,680
New +$160K 0.04% 279

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Harvest Investment Services's ZNTL Position: Q4 2025 in Review

Harvest Investment Services sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 14,206 shares — an estimated $21.5K sold.

Harvest Investment Services first reported a position in ZNTL in Q4 2024 and held it in 4 quarters. The position peaked at $148K in Q4 2024. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • Harvest Investment Services reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Harvest Investment Services sold 14,206 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $21.5K.
  • Harvest Investment Services first reported a position in Zentalis Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Harvest Investment Services's Zentalis Pharmaceuticals position peaked at $148K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Harvest Investment Services's 13F filing for Q4 2025, filed 17 Feb 2026.